Maximising the potential of AKT inhibitors as anti-cancer treatments.
View/ Open
Date
2017-04-01ICR Author
Author
Brown, JS
Banerji, U
Type
Journal Article
Metadata
Show full item recordAbstract
PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a central component of the pathway, influencing multiple processes that are directly involved in tumourigenesis. Targeting AKT is therefore a highly attractive anti-cancer strategy with multiple AKT inhibitors now in various stages of clinical development. In this review, we summarise the role and regulation of AKT signalling in normal cellular physiology. We highlight the mechanisms by which AKT signalling can be hyperactivated in cancers and discuss the past, present and future clinical strategies for AKT inhibition in oncology.
Collections
Subject
Animals
Humans
Neoplasms
Antineoplastic Agents
Protein Kinase Inhibitors
Signal Transduction
Drug Design
Proto-Oncogene Proteins c-akt
Phosphatidylinositol 3-Kinase
Research team
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Language
eng
Date accepted
2016-11-16
License start date
2017-04
Citation
Pharmacology & therapeutics, 2017, 172 pp. 101 - 115
Publisher
PERGAMON-ELSEVIER SCIENCE LTD